{'fraction_non_alphanumeric': 0.02026431718061674, 'fraction_numerical': 0.006167400881057269, 'mean_word_length': 5.311111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of HIV infection during pregnancy: new options, new questions.


 ACTG 076 demonstrated that the frequency of perinatal HIV transmission can be reduced by administering AZT to HIV-infected pregnant women and their newborns. The rate of vertical transmission in ACTG 076 was approximately eight percent, or one-third of the rate among infants of untreated mothers. This information has affected the clinical management of HIV-infected pregnant women. Commonly raised questions address the validity of HIV testing and counseling for all pregnant women; the effects of pregnancy on HIV disease progression; the times in pregnancy when AZT treatment is appropriate; the relation of CD4 counts to AZT administration; the administration of other antiviral medications to women who have developed resistance to AZT; the recommended prophylactic therapy for opportunistic infections; the prevention of primary toxoplasma and CMV infection; the management of labor; and the benefits of AZT. These questions are answered in the context of clinical, ethical, and cost-benefit issues as they relate to pregnant women and their infants.
